Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the injection and the tablet actually compare, facts, not headlines
The biggest misconception worth clearing up first
A lot of people searching this topic expect to find a tirzepatide tablet they can switch to when needles feel daunting. That product exists in early research but holds no UK licence for weight management as of mid-2026. What the MHRA did license in June 2026 was oral semaglutide (Wegovy tablets), the first oral GLP-1 approved in the UK for weight loss. It is a different drug working through a single GLP-1 receptor pathway, where Mounjaro activates both GIP and GLP-1 receptors simultaneously. The distinction matters clinically. If someone has pointed you toward an oral tirzepatide and suggested it is already available for weight management in the UK, that information is out of date at best.
Equally important: Rybelsus, the oral semaglutide tablet you may have heard of, is licensed only for type 2 diabetes in the UK. It is not Wegovy and cannot be prescribed for weight loss. The molecule is the same; the licence is not. A prescriber cannot lawfully issue Rybelsus for a weight-management purpose under its current authorisation.
What each medicine actually involves day to day
Mounjaro arrives as a pre-filled KwikPen designed for subcutaneous tirzepatide injection, each pen delivers four once-weekly doses. In practice, you take it out of the fridge, attach a needle, choose an injection site on your abdomen, thigh or upper arm, and inject. The pen itself is compact; most people tell our prescribers the process feels routine within a week or two. If you want a clearer picture of the technique, the step-by-step injection guide walks through it. The pen travels in a cool bag; exact room-temperature windows are set out in the Patient Information Leaflet because they matter and vary.
Oral semaglutide (Wegovy tablets) removes the needle entirely. One tablet, first thing in the morning, before any food or drink except a small amount of plain water. You wait at least 30 minutes before your morning coffee or breakfast. No fridge required, which makes it noticeably more straightforward when travelling. The trade-off is strict adherence to that morning routine, eating or drinking too soon meaningfully reduces absorption. According to data from the OASIS 4 phase 3 trial, participants who stayed fully adherent lost around 17% of their body weight over 64 weeks; the average across all participants, regardless of adherence, was roughly 13.6%. That difference reflects how much the timing rule matters in practice.
Comparing the evidence side by side
The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at tirzepatide 15mg over 72 weeks in adults with obesity and without diabetes. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide 2.4mg injection over the same period. NICE's appraisal of tirzepatide (TA1026) reflects that body of evidence. Oral semaglutide's ~13.6% average sits below those figures, though direct head-to-head data between the tablet and the injection are not yet available. Numbers from separate trials, run in different populations, cannot be stacked cleanly.
| Feature | Mounjaro (tirzepatide injection) | Wegovy tablets (oral semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Administration | Once-weekly subcutaneous injection | Once-daily tablet |
| Average weight loss (headline trial figure) | ~20–21% at 15mg (SURMOUNT-1, 72 weeks, cited above) | ~13.6% average; ~17% fully adherent (OASIS 4, 64 weeks) |
| Storage | Refrigerated (2–8°C); see leaflet for travel window | Room temperature; no fridge needed |
| UK licence for weight management | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes, from June 2026 (BMI ≥30, or ≥27 with a weight-related condition) |
| NICE recommendation | Yes, TA1026 (published December 2024, updated September 2025) | No NICE appraisal yet; private prescription only at launch |
The NICE tirzepatide appraisal (TA1026) sets out eligibility criteria for NHS access. Wegovy tablets have no equivalent NICE recommendation yet, so they are available only via private prescription for now. Both are Black Triangle medicines, meaning the MHRA keeps them under additional monitoring while post-market data accumulates.
Eligibility, needles, and who decides
Needle anxiety is real, and it is one of the most common things people raise during consultations. It is a perfectly legitimate clinical factor. At the same time, the trial evidence for injectable tirzepatide is currently more substantial than for the oral tablet, and the NICE recommendation carries weight when a prescriber is assessing what is appropriate for you. Neither of those things means you must choose the injection. A prescriber reviews your full picture (BMI, health conditions, relevant history, how you feel about each option) and that conversation shapes the recommendation. If you are weighing up whether tirzepatide comes in an oral or injectable form, that is a good place to start before your consultation. You can read more about Mounjaro or explore how the KwikPen works, including details on the injection needle used with each dose, before you start.
Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. That detail, and how it interacts with which medicine a prescriber might recommend, is something our clinical team works through individually. Worth checking before you assume you don't qualify. Our clinical team handles the review personally, not by algorithm. Which medicine suits you is a decision made with your prescriber, not before you speak to one.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.